EMA starts first rolling review of COVID-19 vaccine

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has started the first ‘rolling review’ of a COVID-19 vaccine, which is being developed by AstraZeneca in collaboration with the University of Oxford.

The start of the rolling review means that the committee has started evaluating the first batch of data on the vaccine, which come from laboratory studies (non-clinical data).

This does not mean that a conclusion can be reached yet on the vaccine’s safety and effectiveness, as much of the evidence is still to be submitted to the committee.

A rolling review is one of the regulatory tools that the Agency uses to speed up the assessment of a promising medicine or vaccine during a public health emergency.

Normally, all data on a medicine’s effectiveness, safety and quality and all required documents must be submitted at the start of the evaluation in a formal application for marketing authorisation.

In the case of a rolling review, the CHMP reviews data as they become available from ongoing studies, before deciding that sufficient data are available and that a formal application should be submitted by the company.

The CHMP’s decision to start the rolling review of the vaccine is based on preliminary results from non-clinical and early clinical studies suggesting that the vaccine triggers the production of antibodies and T cells (cells of the immune system, the body’s natural defences) that target the virus.

Large-scale clinical trials involving several thousands of people are ongoing, and results will become available over the coming weeks and months.

These results will provide information on how effective the vaccine is in protecting people against COVID-19 and will be assessed in later rolling review cycles.

All the available data on the safety of the vaccine emerging from these studies, as well as data on its quality (such as its ingredients and the way it is produced), will also be reviewed.

The rolling review will continue until enough evidence is available to support a formal marketing authorisation application.

EMA will complete its assessment according to its usual standards for quality, safety and effectiveness. While the overall review timeline cannot be forecast yet, the process should be shorter than a regular evaluation due to the time gained during the rolling review.

The rolling review process has been used previously in the assessment of the COVID-19 medicine, Veklury (remdesivir).

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...

Moderna regains rights to RSV vaccine from Merck

Moderna has regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. mRNA-1172,...

Takeda & Arrowhead to co-develop RNAi therapy for AATLD

Takeda and Arrowhead Pharmaceuticals will collaborate to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver...

Related news

CHMP recommends ViiV’s long-acting regimen for HIV

The Committee for Medicinal Products for Human Use (CHMP) has recommended ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in combination with Rekambys (rilpivirine injection)...

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...